Orion - Company Announcement

Publishing of Orion Corporation's Interim Report for January-September 2016 on 25 October 2016

ORION CORPORATION     STOCK EXCHANGE RELEASE   11 OCTOBER 2016 at 9:00 A.M. EEST

Publishing of Orion Corporation's Interim Report for January-September 2016 on
25 October 2016


Orion will publish its Interim Report for January-September 2016 on Tuesday, 25
October 2016 approximately at 12:00 noon Finnish time (EEST). The release and
related presentation material in Finnish and in English will be available on the
Group's homepage at www.orion.fi/en/investors promptly after the publishing.
News conference for analysts and media

A news conference for analysts and media will be held on Tuesday, 25 October
2016 at 13:30 EEST at Hotel Kämp, address Pohjoisesplanadi 29, Helsinki.
President and CEO Timo Lappalainen will give a brief presentation in English on
the financial review. Questions can be asked after the result presentation.

Participants should be prepared to present a photo ID on request.
Live webcast and conference call

A link to the live webcast will be available at Orion's website
www.orion.fi/en/investors.

The conference call ID is 3897800 and the phone numbers to participate the
conference are:
 Finland: +358 (0)9 7479 0404

 Sweden:  +46 (0)8 5065 3942

 UK:      +44 (0)20 7026 5967

 USA:     +1 719-325-2202



News conference recordings

A recording of the event in English and a recording of the presentation by the
President and CEO in Finnish will be available on the Orion website later the
same day.
Silent period

The silent period preceding the publication is ongoing and continues until the
disclosure.


Orion Corporation



 Timo Lappalainen  Jari Karlson
 President and CEO CFO


Contact person:
Tuukka Hirvonen, Communications Manager, IR & Financial Communications
tel. +358 10 426 2721


Publisher:
Orion Corporation
www.orion.fi/en


Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. The core therapy areas of Orion's pharmaceutical R&D are
central nervous system (CNS) disorders, oncology and respiratory for which Orion
developes inhaled Easyhaler® pulmonary drugs.

Orion's net sales in 2015 amounted to EUR 1,016 million and the company had
about 3,400 employees. Orion's A and B shares are listed on Nasdaq Helsinki.

[]